Diamyd Medical submits application to the Medical Products Agency for the DIAGNODE-2 trial

Diamyd Medical today announced that the Company has submitted an application to the Swedish Medical Products Agency to conduct DIAGNODE-2, a pivotal follow-up clinical trial in children and adolescents recently diagnosed with type 1 diabetes. The placebo-controlled Phase II trial will investigate an innovative and patent-pending concept, where the diabetes vaccine Diamyd® is administered directly into the lymph nodes. The trial will be conducted in Sweden, Spain and the Czech Republic at selected diabetes clinics, with established contacts and interests to achieve the best possible